A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

PURPOSE: The combination of afatinib, an irreversible ErbB family blocker, with paclitaxel and bevacizumab was assessed in patients with advanced solid tumors. METHODS: This phase I study used a 3 + 3 design to determine the maximum tolerated dose (MTD) of afatinib combined with paclitaxel and bevac...

Descripción completa

Detalles Bibliográficos
Autores principales: Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225194/
https://www.ncbi.nlm.nih.gov/pubmed/27872953
http://dx.doi.org/10.1007/s00280-016-3189-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225194/
https://www.ncbi.nlm.nih.gov/pubmed/27872953
http://dx.doi.org/10.1007/s00280-016-3189-1

Ejemplares similares